ArticleCurrent cardiovascular risk reports2013
Metformin in Diabetic Patients with Heart Failure: Safe and Effective?
Article in Current cardiovascular risk reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- More on the Magic of Metformin.Cardiology · 2023Article
- Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing.PLoS pathogens · 2021Review
- Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.Heart failure clinics · 2020Review
- Improvement of insulin signalling rescues inflammatory cardiac dysfunction.Scientific reports · 2019Article
- Clinical impact of oral antidiabetic medications in heart failure patients.Heart failure reviews · 2018Review
- Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.Current heart failure reports · 2017Review
- Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.Journal of the American Heart Association · 2017Article
- Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.International journal of molecular sciences · 2016Article
- The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.Metabolic syndrome and related disorders · 2015Review
- SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?Current cardiovascular risk reports · 2015Article
- Metformin as a cellular protector; a synoptic view of modern evidences.Journal of nephropharmacology · 2015Review
- Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis.Cardiology · 2015Review
- Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Management of diabetic patients with heart failure is a complex endeavor. The initial reluctance to use metformin in these patients has given way to a broader acceptance after clinical trials and meta-analyses have revealed that some of the insulin-sensitizing agents lead to adverse cardiovascular events. We have proposed that an increase of substrate uptake by the insulin-resistant heart is detrimental because the heart is already flooded with fuel. In light of this evidence, metformin offers a unique safety profile in the patient with diabetes and heart failure. Our article expands on the use of metformin in patients with heart failure. We propose that the drug targets both the source as well as the destination (in this case the heart) of excess fuel. We consider treatment of diabetic heart failure patients with metformin both safe and effective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.